Study guide

7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care

AACN Cardiac Medicine Certification CMC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview and the CMC Test Plan

1.1 CMC Exam Format, Eligibility, Fees & Scoring 1.2 The CMC Test Plan: Four Domains and How to Study Them

2 Chapter 2: Acute Coronary Syndromes and Ischemic Heart Disease

2.1 Pathophysiology & Classification of Acute Coronary Syndromes 2.2 12-Lead ECG Localization & Cardiac Biomarker Trajectories 2.3 Acute Reperfusion Strategies & Nursing Management 2.4 Complications of Acute Myocardial Infarction 2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy

3 Chapter 3: Heart Failure, Cardiomyopathies, Pericardial and Valvular Disease

3.1 Acute Decompensated Heart Failure & Staging 3.2 Acute Cardiogenic Pulmonary Edema 3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies 3.4 Acute Pericarditis, Cardiac Tamponade & Constrictive Pericarditis 3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease 3.6 Valvular Heart Disease: Stenosis & Regurgitation 3.7 Syncope: Cardiac Versus Non-Cardiac Causes and Workup

4 Chapter 4: Dysrhythmias, Conduction Disorders and Electrophysiologic Interventions

4.1 Atrial Fibrillation, Atrial Flutter & Supraventricular Tachycardias 4.2 Ventricular Arrhythmias & Cardiac Arrest Management 4.3 Atrioventricular Blocks & Intraventricular Conduction Delays 4.4 Temporary Pacing: Transcutaneous, Transvenous and Epicardial 4.5 Permanent Pacemakers, CRT and Device Troubleshooting 4.6 Implantable and Wearable Cardioverter Defibrillators 4.7 Catheter Ablation and Post-Ablation Nursing Care 4.8 Synchronized Cardioversion and Defibrillation

5 Chapter 5: Vascular Conditions and Vascular Interventions

5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises 5.2 Peripheral Artery Disease & Acute Limb Ischemia 5.3 Acute Venous Thrombosis, DVT and VTE Prophylaxis 5.4 Peripheral and Carotid Angiography and Interventions 5.5 Endovascular Aortic Repair: EVAR and TEVAR 5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications

6 Chapter 6: Shock States and Mechanical Circulatory Support

6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies 6.2 Non-Cardiogenic Shock: Hypovolemic, Distributive and Obstructive 6.3 Multisystem Organ Dysfunction Syndrome 6.4 Intra-Aortic Balloon Pump Therapy & Waveform Optimization 6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD

7 Chapter 7: Cardiac Procedures and Structural Heart Interventions

7.1 Diagnostic Cardiac Catheterization & Coronary Angiography Interpretation 7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care 7.3 Structural Heart Interventions: TAVR, MitraClip, Pericardiocentesis 7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications

8 Chapter 8: Cardiovascular Pharmacology

8.1 Inotropes, Vasopressors & Inodilators 8.2 Vasodilators & Antianginal Agents 8.3 Antiarrhythmic Agents: Vaughan Williams Classes I-IV 8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents 8.5 Diuretics and Decongestion Strategies 8.6 Guideline-Directed Medical Therapy for Heart Failure

9 Chapter 9: Non-Cardiovascular Conditions: Pulmonary

9.1 Acute Pulmonary Embolism 9.2 Acute Respiratory Failure and ARDS 9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax 9.4 Pulmonary Hypertension and Right Ventricular Failure 9.5 Sleep-Disordered Breathing in Cardiac Patients

10 Chapter 10: Non-Cardiovascular Conditions: Endocrine, Renal, Hematologic, Neurologic and Behavioral

10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care 10.2 Thyroid and Adrenal Disorders in the Cardiac Patient 10.3 Metabolic Syndrome and Cardiometabolic Risk 10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders 10.5 Anemia and Transfusion Management in Cardiac Patients 10.6 Acute Ischemic and Hemorrhagic Stroke in the Cardiac Patient 10.7 Acute Kidney Injury and Contrast-Associated Nephropathy 10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient 10.9 Electrolyte Imbalances and Dysrhythmia Risk 10.10 Substance Use, Withdrawal and Cardiac Effects 10.11 Non-Cardiac Chest Pain: Differential and Triage 10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients

11 Chapter 11: Monitoring and Diagnostics

11.1 Pulmonary Artery Catheterization & Hemodynamic Waveform Interpretation 11.2 Arterial Line Monitoring, Continuous Cardiac Output & ScvO2 11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging 11.4 Stress Testing and Myocardial Perfusion Imaging 11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices 11.6 Laboratory Testing in Cardiac Care 11.7 Arterial Blood Gases and Acid-Base Interpretation 11.8 Pulse Oximetry, Capnography and Chest Radiography

12 Chapter 12: Respiratory, Renal and Multisystem Therapeutic Interventions

12.1 Non-Invasive Ventilation in Cardiac Patients 12.2 Invasive Mechanical Ventilation and Heart-Lung Interactions 12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration 12.4 Targeted Temperature Management After Cardiac Arrest 12.5 Palliative and End-of-Life Care in Advanced Cardiac Disease

7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care

Key Takeaways Explain This Topic AI

Current-generation drug-eluting stents are standard of care with restenosis under 5%; bioresorbable scaffolds were withdrawn in 2017 for excess scaffold thrombosis and are not a correct exam answer.

No-reflow is a microvascular problem treated with intracoronary adenosine 30-100 mcg, nicardipine 100-300 mcg, verapamil 100-200 mcg, or nitroprusside 50-200 mcg delivered distally - nitroglycerin dilates epicardial vessels and does not treat it.

Stent thrombosis is categorized as acute (under 24 hours), subacute (24 hours to 30 days), late (30 days to 1 year), and very late (over 1 year); it presents as STEMI with 20-40% mortality, whereas restenosis presents as gradual recurrent exertional angina.

In acute myocardial infarction complicated by cardiogenic shock, culprit-lesion-only PCI is preferred, because routine immediate multivessel PCI increased 30-day death and renal replacement therapy.

Default DAPT after ACS is at least 12 months, but transition to ticagrelor monotherapy 1 month or more after PCI roughly halves major bleeding in patients who have tolerated dual therapy.

Last updated: August 2026

From Balloon to Current-Generation Stent

Test-plan item III.A.3 covers percutaneous coronary intervention (PCI) itself. Reperfusion timing for ST-elevation myocardial infarction is taught elsewhere in this guide; here the subject is the procedure, its hardware, its failures, and the post-procedure surveillance that belongs to the nurse.

Device generation Mechanism and limitation Restenosis rate Minimum DAPT

Plain balloon angioplasty (POBA) Fractures plaque; limited by elastic recoil, negative remodeling, and abrupt closure in about 5% 30-40% Not stent-dependent

Bare-metal stent (BMS) Scaffolds against recoil but provokes neointimal hyperplasia 20-30% 1 month

First-generation DES (sirolimus, paclitaxel) Durable polymer suppresses neointima but delays endothelialization, causing late and very late stent thrombosis Under 10% 12 months historically

Current-generation DES (everolimus, zotarolimus on thin-strut cobalt- or platinum-chromium, biocompatible or bioabsorbable polymer) Standard of care; rapid endothelialization with durable antiproliferative effect Under 5% As short as 1 month in high bleeding risk

Bioresorbable scaffold (BRS) Intended to vanish and restore vasomotion; the everolimus polylactide device was withdrawn in 2017 for excess scaffold thrombosis Higher than DES Not standard of care

The exam trap is treating bioresorbable scaffolds as the current best option. They are not. Current-generation drug-eluting stents are the default , and the meaningful modern decisions are about lesion preparation, imaging guidance, and antiplatelet duration - not about which scaffold vanishes.

Imaging and Physiology in the PCI Decision

Fractional flow reserve (FFR) at or below 0.80 and instantaneous wave-free ratio (iFR) at or below 0.89 define a physiologically significant lesion; those thresholds and the IVUS-versus-OCT comparison are covered in the diagnostic catheterization section. What matters here is how the data changes the intervention. Intravascular ultrasound (IVUS) or optical coherence tomography (OCT) guidance reduces target-lesion failure compared with angiography alone by sizing the vessel correctly and confirming stent expansion. Practical targets are a minimal stent area above roughly 5.5 mm2 in a non-left-main vessel and above roughly 7 mm2 in the left main. Imaging also quantifies calcium: a calcium arc exceeding 180 degrees over a segment of 5 mm or more, or calcium thicker than 0.5 mm on OCT, predicts stent underexpansion and mandates calcium modification before stenting. Underexpansion is the leading mechanical cause of both stent thrombosis and restenosis, which is why "just put a stent in it" is the wrong answer for a heavily calcified lesion.

Calcium Modification and Complex Subsets

Rotational atherectomy uses a diamond-coated burr at 140,000-180,000 rpm to ablate calcium differentially. Nursing-relevant risks: slow flow from particulate embolization, burr entrapment, coronary perforation, and bradycardia or transient heart block , particularly in the right or dominant coronary artery - have transcutaneous pacing immediately available and expect the operator to run short ablation passes.

Orbital atherectomy uses an eccentrically mounted diamond crown and sands bidirectionally.

Intravascular lithotripsy delivers acoustic pressure pulses of roughly 50 atmospheres from a balloon to fracture both superficial and deep calcium. Pulses are ECG-gated, and the nurse may see paced-appearing capture beats on the monitor during delivery - a recognized, benign phenomenon.

Bifurcation lesions are preferentially treated with a provisional single-stent strategy, reserving two-stent techniques (culotte, double-kissing crush, T-and-protrusion) for complex anatomy, and finishing with kissing-balloon inflation. Side-branch occlusion is the characteristic complication.

Left main PCI is an accepted alternative to bypass surgery in patients with low-to-intermediate anatomic complexity; intravascular imaging is close to mandatory, and distal left main bifurcation disease is the harder subset.

Chronic total occlusion PCI uses antegrade wire escalation, antegrade dissection re-entry, or retrograde collateral approaches. These are long cases with large contrast and radiation loads and higher perforation and donor-vessel injury risk. The accepted indication is symptom relief, not mortality reduction.

Complete Versus Culprit-Only Revascularization

In STEMI with multivessel disease and non-complex non-culprit lesions, complete revascularization - during the index procedure or as a staged procedure - reduces cardiovascular death and myocardial infarction. The exception is the exam question : in acute myocardial infarction with cardiogenic shock, routine immediate multivessel PCI increased 30-day death and renal replacement therapy compared with a culprit-lesion-only strategy. Shock changes the answer.